Omni Biotech Innovations Ltd.

Omni Biotech Innovations Ltd. is an early-stage Canadian drug discovery company focused on developing multi-specific antibody therapies for autoimmune diseases. The company utilizes a proprietary engineering platform to integrate validated antibody fragments against specific targets, aiming to address the high prevalence and low remission rates associated with existing autoimmune treatments. By leveraging systems-guided design, the company seeks to create novel therapeutics that selectively target B-cell populations and receptor molecules, with initial pipeline assets including OBTI001. Their development model emphasizes cost-efficient research and development, supported by facilities and operations spanning Canada and China.

The company's focus is to provide durable disease control while preserving immune function, addressing significant unmet needs in both prevalent conditions such as Rheumatoid Arthritis and rare diseases like Myasthenia Gravis. By targeting the underlying causes of autoimmunity, they aim to improve patient outcomes and enable better long-term disease management. As a member of the life sciences community and a participant in global biotech partnering forums, Omni Biotech Innovations collaborates with strategic partners to accelerate the advancement of its therapeutic candidates from conceptualization through early-stage clinical enablement.